Description
Metoclopramide is not used in the treatment of colorectal cancer but rather as an antiemetic and prokinetic agent. It has no direct effect on tumor growth or metastasis; its use in CCR patients would be limited to managing side effects from other treatments such as chemotherapy-induced nausea.
Mechanism of Action
Metoclopramide is a dopamine D2 receptor antagonist and serotonin 5-HT4 receptor agonist, which increases gastrointestinal motility by enhancing acetylcholine release.
Side Effects
Akathisia; extrapyramidal symptoms; tardive dyskinesia; sedation; hypoglycemia in diabetic patients
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
NCT02481219
Not Applicable
Archived
Optimization of the Bowel Preparation Regimen for the PillCam® COLON 2 Capsule Endoscopy Procedure
United States